Discounted Cash Flow Rating

Buy

Return on Equity Rating

Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Sarepta Therapeutics,, Inc. Common Stock (SRPT)

Pharmaceutical Preparations

https://www.sarepta.com

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.

215 FIRST STREET, SUITE 415
CAMBRIDGE, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/04/1997

Market Cap

12,821,999,035

Shares Outstanding

93,550,000

Weighted SO

93,546,681

Total Employees

N/A

Upcoming Earnings

08/07/2024

Similar Tickers

RETA --.--%

MRTX --.--%

KRYS --.--%

ICPT --.--%

PTCT --.--%

IOVA --.--%

MDGL --.--%

VKTX --.--%

HEPA --.--%

Beta

0.8850

Last Div

0.0000

Range

55.25-173.25

Chg

1.1100

Avg Vol

1949987

Mkt Cap

12821999035

Exch

NASDAQ

Country

US

Phone

617 274 4000

DCF Diff

14.8018

DCF

137.6920

Div Yield

0.0000

P/S

8.5196

EV Multiple

228.1948

P/FV

11.8111

Div Yield %

0.0000

P/E

268.9682

PEG

7.7981

Payout

0.0000

Current Ratio

3.8979

Quick Ratio

3.1923

Cash Ratio

0.5572

DSO

95.1333

DIO

958.3309

Op Cycle

1053.4642

DPO

211.9022

CCC

841.5620

Gross Margin

0.8771

Op Margin

0.0252

Pretax Margin

0.0413

Net Margin

0.0314

Eff Tax Rate

0.2399

ROA

0.0138

ROE

0.0517

ROCE

0.0139

NI/EBT

0.7601

EBT/EBIT

1.6380

EBIT/Rev

0.0252

Debt Ratio

0.3581

D/E

1.1386

LT Debt/Cap

0.5131

Total Debt/Cap

0.5324

Int Coverage

-5.1466

CF/Debt

-0.3233

Equity Multi

3.1792

Rec Turnover

3.8367

Pay Turnover

1.7225

Inv Turnover

0.3809

FA Turnover

3.7606

Asset Turnover

0.4395

OCF/Share

-4.1905

FCF/Share

-5.5810

Cash/Share

15.4355

OCF/Sales

-0.2635

FCF/OCF

1.3318

CF Coverage

-0.3233

ST Coverage

-4.3331

CapEx Coverage

-3.0138

Div&CapEx Cov

-3.0138

P/BV

11.8111

P/B

11.8111

P/S

8.5196

P/E

268.9682

P/FCF

-24.2814

P/OCF

-32.0845

P/CF

-32.0845

PEG

7.7981

P/S

8.5196

EV Multiple

228.1948

P/FV

11.8111

DPS

0.0000

Latest Headlines (EST)

Benzinga Jul 17, 05:43 Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results GlobeNewswire Inc. Jul 16, 23:53 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm GlobeNewswire Inc. Jul 12, 19:37 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers, Sarepta, and Petco and Encourages Investors to Contact the Firm GlobeNewswire Inc. Jul 11, 00:40 ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT GlobeNewswire Inc. Jul 05, 15:40 INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. (SRPT) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit GlobeNewswire Inc. Jul 03, 23:33 Sarepta Therapeutics, Inc. Class Action Notice: Robbins LLP Reminds SRPT Stockholders of the Lead Plaintiff Deadline in the SRPT Class Action Lawsuit GlobeNewswire Inc. Jun 29, 20:00 SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit GlobeNewswire Inc. Jun 28, 14:00 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT GlobeNewswire Inc. Jun 26, 21:45 DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics GlobeNewswire Inc. Jun 26, 21:38 Sarepta Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 25, 2025 Deadline to file Lead Plaintiff Motion. Benzinga Jun 26, 21:25 SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm GlobeNewswire Inc. Mar 18, 22:16 Sarepta Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm The Motley Fool Jan 22, 17:47 Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today The Motley Fool Jan 22, 17:47 Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today Zacks Investment Research Jan 22, 14:42 AstraZeneca's (AZN) Imfinzi Combo Meets Liver Cancer Study Goal Zacks Investment Research Jan 19, 13:09 TransCode (RNAZ) Down 50% on Issue of New Common Stock Zacks Investment Research Jan 15, 12:27 Iovance (IOVA) Surges More Than 150% in 3 Months: Here's Why Zacks Investment Research Jan 15, 12:27 Iovance (IOVA) Surges More Than 150% in 3 Months: Here's Why Benzinga Jan 09, 12:58 Sarepta Expects Prelim Gene Therapy Revenue To Be $131M In Q4, $200M For Fiscal Year Benzinga Jan 04, 14:08 Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024

Revenue Product Segmentation